UBS Knock-Out BIIB/ DE000UM38U69 /
2024-05-22 2:11:04 PM | Chg.0.000 | Bid2:18:42 PM | Ask2:18:42 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.150EUR | 0.00% | 1.150 Bid Size: 10,000 |
1.210 Ask Size: 10,000 |
Biogen Inc | 102.277 USD | 2078-12-31 | Call |
GlobeNewswire
1:30 PM
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
04-29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...